OBJECTIVES: Partial breast irradiation (PBI) can be considered a safe alternative to standard whole breast irradiation (WBI) in favourable early breast cancer and, profitably, is delivered in a shorter time. Four different techniques have been described in randomized trials (follow-up Ͼ 4 years): intraoperative-radiotherapy (IORT), delivered at the time of tumorectomy; low-dose-rate brachytherapy (LDR), delivered in 3 days; external-beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR), both delivered in 5 days. For comparison, WBI is delivered in seven weeks. The objective of this study was to compare the cost-effectiveness of the 4 different technical approaches to PBI, for the treatment of selected favourable early stage breast cancer patients, using current cost estimations within the Spanish Public Health System. METHODS: A decision-analysis model was performed using efficacy data from previous prospective trials, calculated in years without mastectomy (YWM). Direct costs were estimated based on charges applied by Madrid's Autonomous Community, and were expressed in Euros (€). For each modality of PBI, local recurrence rates where individualized, and charges weighted for the frequency of its occurrence. A probabilistic sensitivity analysis was conducted to evaluate the robustness of the results. RESULTS: A total cost of 5488.25 € was estimated for EBRT, 6595.87 € for LDR, 7454.10 € for HDR, and 8895,71 € for IORT. The incremental cost-effectiveness ratio (ICER) comparing IORT to EBRT was 17209.41 €/YWM. All brachytherapy techniques (LDR and HDR) were dominated. Sensitivity analysis showed that ICER depends mainly on recurrence level after EBRT, but also on IORT costs. CONCLUSIONS: In a Spanish Public Health Care scenario, IORT shows a reasonable a cost-effectiveness ratio for patients with early stage breast cancer and, due to its intrasurgical administration (same hospital admission required for surgery), should be considered a compelling alternative, in particular for patients with complex transportation demands to access radiotherapy facilities.
OBJECTIVES:
In breast cancer, adjuvant chemotherapy is often prescribed as a precautionary measure and sometimes unnecessarily. A diagnostic test based on an analysis of 21 genes estimating the risk of recurrence at 10 years for women with breast cancer in early stage has been developed (Oncotype-DX®). A cost-effectiveness model was implemented to evaluate the long-term costs and clinical outcomes associated with introducing this test to inform decision on adjuvant chemotherapy in France. METHODS: A Markov model was implemented to evaluate the impact of the test in terms of costs, life-years gained and quality-adjusted life-years (QALYs) in French clinical practice for patients with ER ϩ, HER2-, nodenegative early-stage breast cancer, over 30 years. A strategy using the genetic test to decide whether to administer chemotherapy or not was compared to utilization of standard decision criteria. The model accounted for the costs of testing, adjuvant chemotherapy and recurrence. Utilities were dependent on recurrence status and undergoing chemotherapy. Input data were obtained from a study evaluating the proportions of patients in which the genetic test led to change the oncologist's decision, as well as scientific literature and grey literature. RESULTS: The test was associated with savings of €570 (€1600 with productivity loss cost) per patient from societal perspective and gains of 0.15 life-years and 0.14 QALYs per patient. Oneway sensitivity analyses showed that the cost was most sensitive to the recurrence cost and QALYs to discount rate and to the proportion of patients for whom the decision not to give chemotherapy was reversed with the test. CONCLUSIONS: The use of the test seems to represent efficient use of health care resources in French practice. This test provides an opportunity to optimize treatment prescription by avoiding unnecessary chemotherapies and by prescribing chemotherapy to women who have not received it based on standard decision criteria. 
PMD52 DIAGNOSTICS IN COST-EFFECTIVENESS ANALYSIS: THE EVALUATION OF THE EOS 2D/3D X-RAY IMAGING SYSTEM

OBJECTIVES:
The EOS 2D/3D X-ray imaging system is a novel technology with potential clinical benefits in the evaluation of orthopaedic conditions. However, there is no evidence on other benefits in addition to those derived from reductions in the radiation dose. This study aims to evaluate the cost-effectiveness of EOS compared with standard X-ray and highlight some of the typical challenges in the evaluation of diagnostics. METHODS: A model was developed to evaluate the longterm cost-effectiveness of EOS. Costs were from a health service perspective and outcomes were measured as quality-adjusted life years (QALYs). Threshold analysis was used to establish the necessary size of the additional health benefits and the level of patient throughput needed for EOS to be considered cost-effective. RESULTS: The incremental cost-effectiveness ratio (ICER) of EOS was well above thresholds of £20,000 and £30,000 per additional QALY in all orthopaedic conditions under base-case assumptions. Patient throughput was a major determinant of cost-effectiveness. Threshold analysis on patient throughput showed that 17,700 to 27,600 scans per year with EOS, compared with 7,530 scans per year with computed radiography (CR), were needed to achieve an ICER of £20,000 per QALY. Health benefits over and above lower radiation would need to increase considerably for EOS to be considered cost-effective. CONCLUSIONS: The health benefits estimated from EOS as a result of radiation dose reductions were insufficient to justify the cost of the system. EOS can only be shown to be cost-effective when compared to CR if the utilisation of EOS is assumed to be about twice the utilisation of CR. EOS highlights some of the difficulties of establishing the relevant care pathway, potential indications, patient benefit from the imaging features, and patient throughput. The evaluation of EOS is an example of how methodological challenges presented by diagnostics can be overcome. 
PMD53 MODELING THE HEALTH AND ECONOMIC CONSEQENCES OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN NON-INSULIN TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
OBJECTIVES:
Evidence from recent clinical studies has shown the benefits of SMBG plus a structured testing program (SMBGϩSTG) in non-insulin treated patients with T2DM. The Structured Testing Protocol (STeP) study found SMBGϩSTG can lead to improvements in glycemic control. This study assessed the cost-effectiveness of SMBGϩSTG versus SMBG alone from the Spanish health care system perspective in the context of recent studies of SMBG that have employed active education programs. METHODS: A discrete event simulation model was developed to simulate the economic and health outcomes based on A1c changes related to using SMBGϩSTG or SMBG alone. Baseline A1c (8.4%) changes over 1 year (-1.2% and -0.9% for SMBGϩSTG versus SMBG alone), discontinuation and hypoglycemia rates were from the STeP study. Population and cost inputs were from published Spanish sources. Over a lifetime horizon (Ͼ30yrs), the model predicts: diabetes related complications (cardiovascular disease, stroke, amputations, end stage renal disease), hypoglycemia, life years (LYs) and quality adjusted life years (QALYs). Costs associated with events were estimated. Benefits and costs were discounted at 5%. Uncertainty in model estimates, such as changes in price per strip, treatment groups, program component, and A1c differences, was explored with sensitivity analyses. RESULTS: SMBGϩSTG was predicted to reduce complications and associated costs. Lowering A1c and consequent complications prevention with SMBGϩSTG translated into a dominant incremental cost-effectiveness ratio. Comparisons with a group not utilizing SMBG yielded similar results. CONCLUSIONS: In the long term, SMBGϩSTG is a cost-effective option compared to SMBG alone. An A1c reduction of 0.3% is a cost-effective outcome. Decison makers should consider designing programs to educate patients about SMBGϩSTG.
PMD54
TRANS-CATHETER AORTIC VALVE IMPLANTATION FOR THE NON-OPERATIVE MANAGEMENT OF AORTIC STENOSIS: A COST-EFFECTIVENESS ANALYSIS
OBJECTIVES:
To assess the cost-effectiveness of TAVI compared with standard therapy consisting mainly of balloon aortic valvuloplasty (BAV) in patients with severe aortic stenosis who are ineligible for conventional aortic valve replacement (AVR) from the perspective of the Ontario health care payer. METHODS: A microsimulation decision analytical model was developed to estimate the incremental costs and benefits associated with both interventions over a lifetime time horizon. Monthly adverse event and patient mortality rates were determined using data from the PARTNER randomized control trial (cohort B). Quality of life values were determined through literature review, expert opinion, and data provided by the PARTNER investigators. The London Health Sciences Centre Case Costing Initiative and the Canadian Institute for Health Administration (CIHI) were used to estimate costs. Extensive sensitivity analyses were performed to explore the impact of uncertainty surrounding model parameters on the resultant cost-effectiveness estimates. The primary outcome measure was the incremental cost-effectiveness ratio (ICER) with benefits expressed as quality-adjusted life years (QALYs). Costs were expressed in 2011 CAD$. Both costs and benefits were discounted at 5%. RESULTS: The base case ICER was approximately $38,448 per QALY gained. The results of the sensitivity analyses yielded ICERs ranging from approximately $32,238/QALY to $43,887/QALY. ICER estimates were most sensitive to changes in the cost of the Edwards SapienTMDevice. CONCLUSIONS: At cost-effectiveness thresholds normally used to define value for money in health care, TAVI represents a cost-effective treatment option for patients with severe aortic stenosis who are currently ineligible to undergo conventional aortic valve replacement in the province of Ontario.
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